证券日报网讯回盛生物11月5日在互动平台回答投资者提问时表示，公司产品结构丰富，以猪用药品为 核心，同时涵盖了家禽、水产、宠物、反刍等其他药品领域。在禽药板块，公司布局了多款中兽药制 剂，如板青颗粒、芪贞增免颗粒、清瘟解毒口服液等。上述产品临床疗效明显，但对禽流感病毒是否有 效还需进一步研究证明。 （文章来源：证券日报） ...

Group 1 - The company emphasizes the importance of communication with the capital market [1] - The company has established a diversified investor communication mechanism [1] - Various forms of communication are utilized, including investor consultation calls, emails, interactive platforms, performance briefings, and participation in major institutional strategy meetings [1]

Core Viewpoint - The company, Reap Bio (300119), is deeply engaged in the pet medicine sector, holding 18 new veterinary drug registration certificates to meet diverse medical needs in pet healthcare [1] Group 1: Product Development - The company focuses on developing key products such as pet vaccines and deworming medications, including advanced products like the cat quadrivalent mRNA vaccine and dog quadrivalent vaccine [1] - Ongoing research includes vaccines for feline infectious peritonitis and various internal medicine and deworming drugs, indicating a strong pipeline of innovative products [1] Group 2: Ecosystem and Collaboration - The company aims to build a comprehensive pet health ecosystem through deep collaboration among its three strategic segments: Reap Bio, Ruipai Pet Hospital, and Zhongrui Supply Chain [1] - This collaboration creates a complete value chain that spans "research - validation - distribution - service," enhancing the overall effectiveness of the company's offerings [1] Group 3: Innovation and Market Strategy - Reap Bio constructs a technological moat through innovative products and continuous breakthroughs in technical barriers, supported by a network of over 10,000 terminals [1] - The company emphasizes a feedback loop of "clinical validation - demand response - precise research and development" to drive innovation [1] - Zhongrui Supply Chain is positioned as a global channel engine, connecting the production, distribution, and consumption ends of the market [1]

Core Viewpoint - The company, Blue Horizon Biological, announced the approval of its subsidiary Qingdao Kangdian Animal Pharmaceutical Co., Ltd. for two new veterinary drugs, "Fluralaner Drops (for dogs)" and "Fluralaner Drops (for cats)", classified as Class II new veterinary drugs by the Ministry of Agriculture and Rural Affairs [2]. Summary by Categories - **Company Announcement** - Blue Horizon Biological has received approval for its subsidiary's new veterinary drugs [2]. - The Ministry of Agriculture and Rural Affairs issued the New Veterinary Drug Registration Certificate (Announcement No. 949) for these products [2]. - **Product Details** - The approved products include "Fluralaner Drops (for dogs)" and "Fluralaner Drops (for cats)" [2].

Core Viewpoint - The company, Reap Bio (300119), announced its share repurchase and dividend distribution plans, highlighting its commitment to returning value to shareholders through significant cash dividends and stock repurchases [1] Group 1: Share Repurchase - In 2023 and 2024, the company plans to repurchase a total of 10.68 million shares [1] - The total amount allocated for the share repurchase is 190 million RMB [1] Group 2: Dividend Distribution - Since its listing, the company has distributed a total of 1.371 billion RMB in cash dividends [1] - The average dividend payout ratio stands at 44.32% [1] - The company has executed four stock splits, resulting in a 5.27 times expansion of its share capital compared to before its initial public offering [1]

Group 1 - The company views the pet pharmaceutical sector as one of its key development directions and is optimistic about its future prospects [2] - The company has adjusted resource allocation to increase investment in pet pharmaceutical research and market channel development [2] - The company has established an independent and specialized research team for pet pharmaceuticals and has obtained seven product approvals in the first half of the year, significantly expanding its product line [2] Group 2 - The company's pet pharmaceutical products mainly cover various subfields, including antiparasitics, analgesics, dermatological medications, internal medicine, and functional health products [2]

Core Viewpoint - The company reported significant growth in both revenue and net profit for the first half of the year, indicating strong operational performance and market demand [1] Financial Performance - The company achieved operating revenue of 822.20 million yuan, an increase of 88.45% compared to the same period last year [1] - The net profit attributable to shareholders reached 117.18 million yuan, reflecting a substantial growth of 325.88% year-on-year [1] Segment Performance - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1] - Sales revenue from veterinary raw materials surged by 199.01% compared to the previous year, with a gross margin improvement of 27.14% [1] Financial Impact - The redemption of convertible bonds led to a reduction in interest expenses by 11.31 million yuan, which had a certain impact on net profit [1] - The company declared a cash dividend of 1.00 yuan per 10 shares to all shareholders [1]